The US Court of Appeals for the Federal Circuit has reportedly affirmed the ruling by the US District Court of New York.
The source has also cited a difference of opinion between the Federal Trade Commission (FTC) and the courts over agreements that delay the availability of cheaper generic versions of drugs. While the FTC considers such agreements as a breach of antitrust law, the courts think otherwise.